Clinical Cancer Research, Vol 1, Issue 10 1071-1077, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Antibody to ras proteins in patients with colon cancer

M Takahashi, W Chen, DR Byrd, ML Disis, ES Huseby, H Qin, L McCahill, H Nelson, H Shimada and K Okuno
Division of Oncology, Departments of Medicine and Surgery, University of Washington, Seattle, Washington 98195, USA.

The current study examined sera from 160 colon cancer patients and 60 normal individuals to determine whether antibody to mutated p21 ras protein was present. Studies focused on the aspartic acid substitution at amino acid position 12 (denoted D12), one of the most common mutations in colon adenocarcinoma. IgA antibodies directed against mutated p21 ras-D12 protein were detected in 51 (32%) of 160 colon cancer patients, but only in 1 (2.5%) of 40 normal individuals. The greater incidence of antibody in cancer patients provides presumptive evidence that immunization to the ras proteins occurred as a result of the malignancy. Examination of sera for antibody reactivity to wild-type p21 ras protein (denoted p21 ras-G12) as well as p21 ras proteins bearing the D12, V12, S12, or L61 mutations showed that antibody detected was largely to normal segments of the p21 ras protein. Epitope mapping, using peptide neutralization assays with mutated or normal ras peptides as competitors, demonstrated that in 10 (67%) of 15 sera examined the antibody reactivity to p21 ras-G12 protein was neutralized by peptides near the carboxyl terminus of p21 ras protein, but not by peptides spanning the specific point mutation region. Antibody reactivities correlated with peripheral blood lymphocyte count, but did not correlate with patient age, sex, histology, stage, tumor locus, lymph node metastasis, or serum carcinoembryonic antigen.

This article has been cited by other articles:

				M. Robin, J. Andreu-Gallien, M.-H. Schlageter, D. Bengoufa, I. Guillemot, K. Pokorna, C. Robert, J. Larghero, P. Rousselot, E. Raffoux, et al. Frequent antibody production against RAR{alpha} in both APL mice and patients Blood, September 15, 2006; 108(6): 1972 - 1974. [Abstract] [Full Text] [PDF]

				R. Somasundaram, R. Swoboda, L. Caputo, L. Otvos, B. Weber, P. Volpe, P. van Belle, S. Hotz, D. E. Elder, F. M. Marincola, et al. Human Leukocyte Antigen-A2-Restricted CTL Responses to Mutated BRAF Peptides in Melanoma Patients. Cancer Res., March 15, 2006; 66(6): 3287 - 3293. [Abstract] [Full Text] [PDF]

				B. Kubuschok, F. Neumann, R. Breit, M. Sester, C. Schormann, C. Wagner, U. Sester, F. Hartmann, M. Wagner, K. Remberger, et al. Naturally Occurring T-Cell Response against Mutated p21 Ras Oncoprotein in Pancreatic Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1365 - 1372. [Abstract] [Full Text] [PDF]

				E. Purev, D. Cai, E. Miller, R. Swoboda, T. Mayer, A. Klein-Szanto, F. M. Marincola, R. Mick, L. Otvos, W. Wunner, et al. Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, {Delta}EGF-R, and de2-7 EGF-R) J. Immunol., November 15, 2004; 173(10): 6472 - 6480. [Abstract] [Full Text] [PDF]

				V. A. Somers, R. J. Brandwijk, B. Joosten, P. T. Moerkerk, J.-W. Arends, P. Menheere, W. O. Pieterse, A. Claessen, R. J. Scheper, H. R. Hoogenboom, et al. A Panel of Candidate Tumor Antigens in Colorectal Cancer Revealed by the Serological Selection of a Phage Displayed cDNA Expression Library J. Immunol., September 1, 2002; 169(5): 2772 - 2780. [Abstract] [Full Text] [PDF]

				C. Bénistant, J.-F. Bourgaux, H. Chapuis, N. Mottet, S. Roche, and J.-P. Bali The COOH-Terminal Src Kinase Csk Is a Tumor Antigen in Human Carcinoma Cancer Res., February 1, 2001; 61(4): 1415 - 1420. [Abstract] [Full Text]

				T. Soussi p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review Cancer Res., April 1, 2000; 60(7): 1777 - 1788. [Abstract] [Full Text]

				N. Brass, A. Racz, C. Bauer, D. Heckel, G. Sybrecht, and E. Meese Role of Amplified Genes in the Production of Autoantibodies Blood, April 1, 1999; 93(7): 2158 - 2166. [Abstract] [Full Text] [PDF]